ibuprofen has been researched along with Kidney Diseases in 35 studies
Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients who required NSAIDs for osteoarthritis or rheumatoid arthritis and were at increased cardiovascular risk were randomly assigned to receive celecoxib, ibuprofen, or naproxen." | 9.22 | Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. ( Bao, W; Beckerman, B; Berger, MF; Borer, JS; Gaffney, M; Graham, DY; Husni, ME; Libby, P; Lincoff, AM; Lüscher, TF; Menon, V; Nissen, SE; Ruschitzka, F; Solomon, DH; Wang, Q; Wisniewski, LM; Wolski, KE; Yeomans, ND, 2016) |
| " We examined whether delayed administration of the nonsteroidal anti-inflammatory agent ibuprofen only or combined with antibiotics suppresses renal scarring in a model of ascending pyelonephritis in rats." | 5.30 | Ibuprofen combined with antibiotics suppresses renal scarring due to ascending pyelonephritis in rats. ( Anderson, AE; Franco, I; Hom, D; Huang, A; Kushner, L; Palmer, LS, 1999) |
| "To determine the relative risks of cardiovascular (CV), gastrointestinal (GI), and renal adverse events during long-term treatment with celecoxib, compared with ibuprofen and naproxen, in patients with osteoarthritis (OA) and patients with rheumatoid arthritis (RA)." | 5.27 | Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis: A Randomized Clinical Trial. ( Bao, W; Berger, MF; Borer, JS; Graham, DY; Husni, ME; Libby, P; Lincoff, AM; Lüscher, TF; Menon, V; Nissen, SE; Solomon, DH; Wang, Q; Wisniewski, LM; Wolski, KE; Yeomans, ND, 2018) |
| "Patients who required NSAIDs for osteoarthritis or rheumatoid arthritis and were at increased cardiovascular risk were randomly assigned to receive celecoxib, ibuprofen, or naproxen." | 5.22 | Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. ( Bao, W; Beckerman, B; Berger, MF; Borer, JS; Gaffney, M; Graham, DY; Husni, ME; Libby, P; Lincoff, AM; Lüscher, TF; Menon, V; Nissen, SE; Ruschitzka, F; Solomon, DH; Wang, Q; Wisniewski, LM; Wolski, KE; Yeomans, ND, 2016) |
| "This study aims to determine whether or not treatment of preterm neonates with PDA using IV ibuprofen can impair renal function and in what range of birth weights and gestational ages the risk of major renal side-effects due to ibuprofen is highest." | 5.17 | Treatment of patent ductus arteriosus (PDA) using ibuprofen: renal side-effects in VLBW and ELBW newborns. ( Bagnoli, F; Casucci, M; Messina, G; Mori, A; Rossetti, A; Tomasini, B, 2013) |
| " Children with a febrile illness were enrolled from outpatient pediatric and family medicine practices and randomly assigned to receive either acetaminophen suspension or one of two dosages of ibuprofen suspension (5 mg/kg or 10 mg/kg) for fever control." | 5.08 | Renal function after short-term ibuprofen use in infants and children. ( Lesko, SM; Mitchell, AA, 1997) |
| "Celecoxib is the first COX-2-specific inhibitor approved for relief of the signs and symptoms of osteoarthritis (OA) and rheumatoid arthritis (RA), as well as for treatment of familial adenomatous polyposis." | 4.80 | Celecoxib clinical profile. ( Tive, L, 2000) |
| "Studies with benoxaprofen in rheumatoid arthritis and osteoarthritis, conducted in more than 2000 patients, continue to demonstrate its safety and effectiveness." | 3.66 | An update on long-term efficacy and safety with benoxaprofen. ( Mikulaschek, WM, 1982) |
| " Documentation is derived from clinical trials, post-marketing surveillance, special studies, and spontaneous reports of adverse drug reactions from foreign countries." | 2.66 | Worldwide safety experience with diclofenac. ( Catalano, MA, 1986) |
| "Since its introduction in the United States in 1974, ibuprofen (Motrin, Upjohn) has been shown to be safe and effective for the treatment of pain, dysmenorrhea, inflammation, and fever." | 2.65 | Safety profile: fifteen years of clinical experience with ibuprofen. ( Royer, GL; Seckman, CE; Welshman, IR, 1984) |
| " Although effective, these agents can be associated with adverse effects that may limit their use in some people." | 2.58 | Cardiorenal Safety of OTC Analgesics. ( Angiolillo, DJ; Davidson, MH; Kloner, RA; White, WB, 2018) |
| "Ibuprofen has recently been introduced as over-the-counter drug in several countries." | 2.38 | Ibuprofen as an over-the-counter drug: is there a risk for renal injury? ( Brune, K; Goerig, M; Luft, FC; Mann, JF, 1993) |
| " These results suggest that even the acute use of an NSAID (regardless of COX-2 selectivity) can induce gastric damage when combined with the long-term use of low-dose aspirin in an animal model." | 1.43 | Gastric and renal effects of COX-2 selective and non-selective NSAIDs in rats receiving low-dose aspirin therapy. ( Baglie, S; Baller, EM; Franco, GC; Gevert, MV; Lupepsa, AC; Moro, MG; Sanchez, PK; Tostes, AF, 2016) |
| "Each ibuprofen-treated infant was matched to two controls." | 1.36 | The renal adverse effects of ibuprofen are not mediated by AQP2 water channels. ( Aperia, A; Hascoët, JM; Vieux, R; Zelenina, M, 2010) |
| " We examined whether delayed administration of the nonsteroidal anti-inflammatory agent ibuprofen only or combined with antibiotics suppresses renal scarring in a model of ascending pyelonephritis in rats." | 1.30 | Ibuprofen combined with antibiotics suppresses renal scarring due to ascending pyelonephritis in rats. ( Anderson, AE; Franco, I; Hom, D; Huang, A; Kushner, L; Palmer, LS, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (25.71) | 18.7374 |
| 1990's | 9 (25.71) | 18.2507 |
| 2000's | 6 (17.14) | 29.6817 |
| 2010's | 10 (28.57) | 24.3611 |
| 2020's | 1 (2.86) | 2.80 |
| Authors | Studies |
|---|---|
| Avdeef, A | 1 |
| Tam, KY | 1 |
| Sridharan, K | 1 |
| Al Jufairi, M | 1 |
| Al Segai, O | 1 |
| Al Ansari, E | 1 |
| Hashem Ahmed, H | 1 |
| Husain Shaban, G | 1 |
| Malalla, Z | 1 |
| Al Marzooq, R | 1 |
| Al Madhoob, A | 1 |
| Saeed Tabbara, K | 1 |
| Solomon, DH | 2 |
| Husni, ME | 2 |
| Wolski, KE | 2 |
| Wisniewski, LM | 2 |
| Borer, JS | 2 |
| Graham, DY | 2 |
| Libby, P | 2 |
| Lincoff, AM | 2 |
| Lüscher, TF | 2 |
| Menon, V | 2 |
| Yeomans, ND | 2 |
| Wang, Q | 2 |
| Bao, W | 2 |
| Berger, MF | 2 |
| Nissen, SE | 2 |
| White, WB | 1 |
| Kloner, RA | 1 |
| Angiolillo, DJ | 1 |
| Davidson, MH | 1 |
| Awad, DS | 1 |
| Ali, RM | 1 |
| Mhaidat, NM | 1 |
| Shotar, AM | 1 |
| Duim, AR | 1 |
| Rokx, C | 1 |
| van Gorp, EC | 1 |
| Rijnders, BJ | 1 |
| Moro, MG | 1 |
| Sanchez, PK | 1 |
| Gevert, MV | 1 |
| Baller, EM | 1 |
| Tostes, AF | 1 |
| Lupepsa, AC | 1 |
| Baglie, S | 1 |
| Franco, GC | 1 |
| Ruschitzka, F | 1 |
| Gaffney, M | 1 |
| Beckerman, B | 1 |
| Vieux, R | 1 |
| Zelenina, M | 1 |
| Aperia, A | 1 |
| Hascoët, JM | 1 |
| Sourbron, S | 1 |
| Bagnoli, F | 1 |
| Rossetti, A | 1 |
| Messina, G | 1 |
| Mori, A | 1 |
| Casucci, M | 1 |
| Tomasini, B | 1 |
| Ackerman, Z | 1 |
| Cominelli, F | 1 |
| Reynolds, TB | 1 |
| Guignard, JP | 1 |
| Ulinski, T | 1 |
| Bensman, A | 1 |
| Singh, H | 1 |
| Agodoa, LY | 1 |
| Francis, ME | 1 |
| Eggers, PW | 1 |
| Royer, GL | 1 |
| Seckman, CE | 1 |
| Welshman, IR | 1 |
| Cinotti, GA | 1 |
| Bender, WL | 1 |
| Whelton, A | 1 |
| Beschorner, WE | 1 |
| Darwish, MO | 1 |
| Hall-Craggs, M | 1 |
| Solez, K | 1 |
| Mikulaschek, WM | 1 |
| Carter, ER | 1 |
| Moffitt, DR | 1 |
| Rudy, AC | 1 |
| Knight, PM | 1 |
| Brater, DC | 2 |
| Hall, SD | 1 |
| Fullerton, T | 1 |
| Sica, DA | 1 |
| Blum, RA | 1 |
| Mann, JF | 1 |
| Goerig, M | 1 |
| Brune, K | 1 |
| Luft, FC | 1 |
| Lesko, SM | 1 |
| Mitchell, AA | 1 |
| Villar, D | 1 |
| Buck, WB | 1 |
| Gonzalez, JM | 1 |
| Huang, A | 1 |
| Palmer, LS | 1 |
| Hom, D | 1 |
| Anderson, AE | 1 |
| Kushner, L | 1 |
| Franco, I | 1 |
| Tive, L | 1 |
| Proctor, RA | 1 |
| Kunin, CM | 1 |
| Murray, MD | 1 |
| Tierney, WM | 1 |
| Hui, SL | 1 |
| McDonald, CJ | 1 |
| Beck, RR | 1 |
| Abel, FL | 1 |
| Papadakis, E | 1 |
| Schlegel, SI | 1 |
| Paulus, HE | 1 |
| Catalano, MA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double Blind, Parallel-group Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen[NCT00346216] | Phase 4 | 24,081 participants (Actual) | Interventional | 2006-10-04 | Completed | ||
| Single Dose Oral Celecoxib (With or Without Acetaminophen) for Acute Post-operative Pain Following Impacted Third Molar Surgery.[NCT04790812] | Phase 4 | 100 participants (Anticipated) | Interventional | 2021-04-22 | Recruiting | ||
| Use of a Self-Guided Mindfulness Mobile Application to Improve Pain Outcomes in Individuals With Knee Osteoarthritis[NCT03936088] | 75 participants (Actual) | Interventional | 2019-05-02 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"VAS question How much pain do you have was graded on a scale from 0 to 100 with 0 indicating No pain and 100 indicating Worst possible pain." (NCT00346216)
Timeframe: ITT and MITT Population - Baseline to 42 months
| Intervention | Number of participants (Mean) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (ITT) N= 8014, 8001, 7928 | Change-Baseline to Mon1 (ITT) N=7382, 7379, 7325 | Change-Baseline to Mon2 (ITT) N=7180, 7090, 7149 | Change-Baseline to Mon4 (ITT) N=6777, 6696, 6740 | Change-Baseline to Mon8 (ITT) N=6230, 6137, 6159 | Change-Baseline to Mon12 (ITT) N=5792, 5696, 5846 | Change-Baseline to Mon18 (ITT) N=5310, 5181. 5246 | Change-Baseline to Mon24 (ITT) N=4818, 4776, 4785 | Change-Baseline to Mon30 (ITT) N=4140, 4069, 4086 | Change-Baseline to Mon36 (ITT) N=3692, 3627, 3635 | Change-Baseline to Mon42 (ITT) N=3469, 3406, 3439 | Baseline (MITT) N=7974, 7954, 7894 | Change-Baseline to Mon1 MITT N=7372, 7367, 7321 | Change-Baseline to Mon2 MITT N=7170, 7078, 7142 | Change-Baseline to Mon4 MITT N=6772, 6686, 6732 | Change-Baseline to Mon8 MITT N=6224, 6128, 6155 | Change-Baseline to Mon12 MITT N=5787, 5689, 5844 | Change-Baseline to Mon18 MITT N=5305, 5175, 5242 | Change-Baseline to Mon24 MITT N=4815, 4769, 4782 | Change-Baseline to Mon30 MITT N=4139, 4067, 4085 | Change-Baseline to Mon36 MITT N=3691, 3623, 3635 | Change-Baseline to Mon42 MITT N=3468, 3404, 3438 | |
| Celecoxib | 54.0 | -8.2 | -10.5 | -11.4 | -11.7 | -11.0 | -11.3 | -11.3 | -10.5 | -10.1 | -11.4 | 54.0 | -8.2 | -10.5 | -11.4 | -11.7 | -11.0 | -11.3 | -11.4 | -10.5 | -10.2 | -11.4 |
| Ibuprofen | 54.1 | -9.0 | -10.6 | -11.7 | -12.1 | -11.6 | -11.3 | -11.5 | -11.2 | -10.7 | -11.1 | 54.1 | -9.0 | -10.6 | -11.7 | -12.1 | -11.6 | -11.3 | -11.5 | -11.2 | -10.7 | -11.1 |
| Naproxen | 54.1 | -9.9 | -11.1 | -12.3 | -12.1 | -11.9 | -11.7 | -11.4 | -11.3 | -11.6 | -12.1 | 54.1 | -9.9 | -11.1 | -12.3 | -12.1 | -11.9 | -11.7 | -11.3 | -11.3 | -11.6 | -12.1 |
MACE defined as the composite of CV death (including hemorrhagic death), non-fatal MI, non-fatal stroke, hospitalization for UA, revascularization or hospitalization for TIA (NCT00346216)
Timeframe: ITT Population - 30 months; MITT Population - 42 months
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| ITT (N = 8072, 8040, 7969) | MITT (N = 8030, 7990, 7933) | |
| Celecoxib | 4.2 | 3.1 |
| Ibuprofen | 4.8 | 3.6 |
| Naproxen | 4.3 | 3.2 |
APTC events are defined as a composite of any of the following events: Death due to CV causes (including cardiac, cerebrovascular, venous thromboembolic, haemorrhagic, other vascular, or unknown cause); Non-fatal MI; Non-fatal stroke (including intracranial hemorrhages, stroke of ischemic or unknown etiology). (NCT00346216)
Timeframe: Intent to Treat (ITT) Population - 30 months; Modified ITT (MITT) Population - 42 months
| Intervention | Percentage of Partcipants (Number) | |
|---|---|---|
| ITT (N = 8072, 8040, 7969) | MITT (N = 8030, 7990, 7933) | |
| Celecoxib | 2.3 | 1.7 |
| Ibuprofen | 2.7 | 1.9 |
| Naproxen | 2.5 | 1.8 |
CSGIE include: Gastroduodenal (GD) hemorrhage, Gastric outlet obstruction, Gastroduodenal, small bowel or large bowel perforation, Large bowel hemorrhage, Small bowel hemorrhage, Acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage, Symptomatic gastric or duodenal ulcer (NCT00346216)
Timeframe: ITT Population - 30 months; MITT Population - 42 months
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| ITT (N = 8072, 8040, 7969) | MITT (N = 8030, 7990, 7933) | |
| Celecoxib | 0.7 | 0.3 |
| Ibuprofen | 0.9 | 0.7 |
| Naproxen | 0.7 | 0.7 |
5 reviews available for ibuprofen and Kidney Diseases
| Article | Year |
|---|---|
Cardiorenal Safety of OTC Analgesics.
Topics: Acetaminophen; Analgesics; Drug Labeling; Heart Diseases; Humans; Ibuprofen; Kidney Diseases; Naprox | 2018 |
Ibuprofen as an over-the-counter drug: is there a risk for renal injury?
Topics: Acute Kidney Injury; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Child; Dose-Response Rela | 1993 |
Ibuprofen, aspirin and acetaminophen toxicosis and treatment in dogs and cats.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; | 1998 |
Celecoxib clinical profile.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celec | 2000 |
Non-steroidal and analgesic therapy in the elderly.
Topics: Acetaminophen; Aged; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents; Apazone; Aspirin; Cen | 1986 |
8 trials available for ibuprofen and Kidney Diseases
| Article | Year |
|---|---|
Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis: A Randomized Clinical Trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celec | 2018 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo | 2016 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo | 2016 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo | 2016 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo | 2016 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo | 2016 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo | 2016 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo | 2016 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo | 2016 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo | 2016 |
Treatment of patent ductus arteriosus (PDA) using ibuprofen: renal side-effects in VLBW and ELBW newborns.
Topics: Birth Weight; Blood Urea Nitrogen; Creatinine; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; | 2013 |
Effect of misoprostol on ibuprofen-induced renal dysfunction in patients with decompensated cirrhosis: results of a double-blind placebo-controlled parallel group study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Female; Glomerular Filtration R | 2002 |
Safety profile: fifteen years of clinical experience with ibuprofen.
Topics: Anti-Inflammatory Agents; Aspirin; Blood Cell Count; Blood Coagulation Tests; Blood Proteins; Centra | 1984 |
Evaluation of the renal protective effect of misoprostol in elderly, osteoarthritic patients at risk for nonsteroidal anti-inflammatory drug-induced renal dysfunction.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Dinoprostone; Double-Blind Method; Female; Glomerular | 1993 |
Renal function after short-term ibuprofen use in infants and children.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Blood Urea Nitroge | 1997 |
Worldwide safety experience with diclofenac.
Topics: Adult; Aged; Aspirin; Chemical and Drug Induced Liver Injury; Child; Clinical Trials as Topic; Diclo | 1986 |
22 other studies available for ibuprofen and Kidney Diseases
| Article | Year |
|---|---|
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological | 2010 |
Biomarkers in neonates receiving potential nephrotoxic drugs.
Topics: Acetaminophen; Adult; Amikacin; Biomarkers; Cystatins; Female; Furosemide; Gentamicins; Hepatitis A | 2021 |
Zizyphus jujuba protects against ibuprofen-induced nephrotoxicity in rats.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Creatinine; Fr | 2014 |
Proximal tubular dysfunction in a HIV-1 patient with coadministered tenofovir disoproxil-fumarate and ibuprofen.
Topics: Anti-HIV Agents; Anti-Inflammatory Agents, Non-Steroidal; HIV Infections; HIV-1; Humans; Ibuprofen; | 2015 |
Gastric and renal effects of COX-2 selective and non-selective NSAIDs in rats receiving low-dose aspirin therapy.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Creatinine; Cycl | 2016 |
The renal adverse effects of ibuprofen are not mediated by AQP2 water channels.
Topics: Analgesics, Non-Narcotic; Aquaporin 2; Birth Weight; Female; Gestational Age; Glomerular Filtration | 2010 |
Compartmental modelling for magnetic resonance renography.
Topics: Adult; Aged; Animals; Anti-Inflammatory Agents, Non-Steroidal; Computer Simulation; Cyclooxygenase I | 2010 |
The adverse renal effects of prostaglandin-synthesis inhibitors in the newborn rabbit.
Topics: Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cycloox | 2002 |
[Renal complications of non-steroidal anti-inflammatories].
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Preschool; Creatinine; Diarrhea; | 2004 |
Treating osteoarthritis in the elderly: should recent data on NSAIDs change our way of practice?
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Databases, Factual; Dicl | 2007 |
Association of analgesic use with prevalence of albuminuria and reduced GFR in US adults.
Topics: Acetaminophen; Adult; Aged; Albuminuria; Analgesics; Aspirin; Cross-Sectional Studies; Female; Glome | 2008 |
Clinical assessment of the renal toxicity of antirheumatic drugs.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Dinoprostone | 1984 |
Interstitial nephritis, proteinuria, and renal failure caused by nonsteroidal anti-inflammatory drugs. Immunologic characterization of the inflammatory infiltrate.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal; Biopsy; Female; Fenoprofen; Fluoresce | 1984 |
Ibuprofen without a prescription.
Topics: Central Nervous System Diseases; Drug Interactions; Female; Hematologic Diseases; Humans; Ibuprofen; | 1984 |
An update on long-term efficacy and safety with benoxaprofen.
Topics: Alkaline Phosphatase; Anemia; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Humans; Ibup | 1982 |
Ibuprofen in patients with cystic fibrosis.
Topics: Child; Cystic Fibrosis; Humans; Ibuprofen; Kidney Diseases | 1995 |
Enantioselective disposition of ibuprofen in elderly persons with and without renal impairment.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Female; Humans; Ibuprofen; Kidney Diseases; Male; Stere | 1995 |
I take ibuprofen regularly for my arthritis, but I've heard that it may lead to kidney damage. Can you tell me more?
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Humans; Ibuprofen; Kidney Diseases | 1999 |
Ibuprofen combined with antibiotics suppresses renal scarring due to ascending pyelonephritis in rats.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Cicatrix; Drug Therapy, Com | 1999 |
Salicylate-induced enzymuria: comparison with other anti-inflammatory agents.
Topics: Acetaminophen; Acetylglucosaminidase; Adult; Anti-Inflammatory Agents; Aspirin; Gold; Hexosaminidase | 1978 |
Ibuprofen-associated renal impairment in a large general internal medicine practice.
Topics: Acetaminophen; Acute Kidney Injury; Adolescent; Adult; Age Factors; Aged; Analysis of Variance; Fema | 1990 |
Influence of ibuprofen on renal function in acutely endotoxemic dogs.
Topics: Animals; Blood Glucose; Dogs; Endotoxins; Ibuprofen; Kidney Diseases; Kidney Function Tests; Male; S | 1989 |